IgE Test in Secretions of Patients with Respiratory Allergy
- 47 Downloads
Purpose of Review
IgE is a key player in multiple inflammatory airway diseases. Ample literature demonstrates its presence in mucosa of patients with allergic rhinitis (AR), local allergic rhinitis (LAR), asthma, or chronic rhinosinusitis with nasal polyposis (CRSwNP).
Current evidence shows that high-affinity IgE in blood stream of allergic individuals derives mainly from the mucosae. Also, mucosal synthesis of IgE can occur in the absence of systemic atopy, and may be relevant in atopic and non-atopic phenotypes of rhinitis as demonstrated in LAR. Specific IgE (sIgE) detection varies depending on technique used for sample collection and its measurement. sIgE detection is highly specific for diagnosis of LAR. Moreover, measurement of sIgE in secretions could be useful in monitoring response to allergen-specific immunotherapy in both AR and LAR phenotypes.
This review will focus on recent developments in the role of IgE in respiratory diseases, and the clinical implications of its measurement in secretions.
KeywordsAllergic IgE Local allergic rhinitis Rhinitis Allergen-specific immunotherapy
The authors’ research is supported by the Institute of Health “Carlos III” of the Ministry of Economy and Competitiveness (grants cofounded by European Regional Development Fund (ERDF)): ARADyAL RD16/0006/0001, FIS PI12/00900, FIS PI14/00864, and FIS PI17/01410; Andalusian Regional Ministry Health grants PI-0346-2016 and PC-0098-2017; and Institute of Health “Carlos III” through its “Rio Hortega” funding scheme (CM17/00140). Dr. Shamji reports grants from Immune Tolerance Network, NIAID, Regeneron, USA, and grants from Biotech Tools, outside the submitted work.
Compliance with Ethical Standards
Conflict of Interest
The authors declare no conflicts of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 17.•• Berings M, Arasi S, De Ruyck N, Perna S, Resch Y, Lupinek C, et al. Reliable mite-specific IgE testing in nasal secretions by means of allergen microarray. J Allergy Clin Immunol. 2017;140(1):301–3 e8. Investigators used a customized microarray containing 15 house dust mite allergen molecules based ImmunoCAP solid-phase allergen chip technology for sIgE detection in nasal secretions of 30 adult patients with AR by house dust mites and 29 non-allergic controls. Samples were obtained with filter disks and sinus packs. Detection of sIgE to at least one of the major allergen molecules (nDer p 1, nDer f 1, rDer p 2, rDer f 2, rDer p23) in nasal secretions predicted with high sensitivity and excellent specificity the allergic status of the patient and the outcome in serum (specificity 100% for both filter disks and sinus packs; sensitivity 90% for filter disks and 87% for sinus packs). CrossRefGoogle Scholar
- 22.• Campo P, Plaza-Seron MC, Eguiluz-Gracia I, Verge J, Galindo L, Barrionuevo E, et al. Direct intranasal application of the solid phase of ImmunoCAP increases nasal specific IgE detection in local allergic rhinitis. Int Forum Allergy Rhinol. 2018;8(1):15–9 This work evaluated a minimally invasive method of direct detection of nasal sIgE (NsIgE) in patients with LAR to D. pteronyssinus (DP). This was performed by direct application of the solid phase of a commercial DP ImmunoCAP® test 24 h after DP nasal provocation in 50 patients (LAR, n = 14; allergic rhinitis (AR), n = 20; healthy controls n = 16). NsIgE ≥0.1450 was the optimal cut-off point, obtaining in LAR patients 42.86% sensitivity with the highest specificity (100%), and 75% sensitivity and 100% specificity for AR, demonstrating the detection of NsIgE to DP in LAR by using a simple, commercial device with high specificity. CrossRefGoogle Scholar
- 26.Ishizaka K. Presence of gammaE in nasal washings and sputum from asthmatic patients. J Allergy Clin Immunol. 1970;46(4):197–204.Google Scholar
- 27.Tse KS, Arbesman CE. IgE antibodies in nasal secretions of ragweed-allergic subjects. J Allergy Clin Immunol. 1970;46(6):352–7.Google Scholar
- 32.• Wu YC, James LK, Vander Heiden JA, Uduman M, Durham SR, Kleinstein SH, et al. Influence of seasonal exposure to grass pollen on local and peripheral blood IgE repertoires in patients with allergic rhinitis. J Allergy Clin Immunol. 2014;134(3):604–12 A study performed in AR subjects and control that exploits next-generation sequencing to determine local and peripheral blood immunoglobulin heavy-chain gene (IGH) repertoires in patients with respiratory allergic disease, demonstrating that natural pollen exposure was associated with changes in IgE repertoires suggestive of ongoing germinal center reactions. These changes were more apparent in nasal biopsy specimens compared with peripheral blood and in patients with AR compared with healthy control subjects. CrossRefGoogle Scholar
- 33.• Ramadani F, Hobson P, Chan YC, Mzinza D, Bowen H, et al. Intrinsic properties of germinal center-derived B cells promote their enhanced class switching to IgE. Allergy. 2015;70(10):1269–77 This article studies the relation between the phenotypic composition of tonsil B cells and the CSR to IgE ex vivo. Naïve, germinal center (GC), early GC (eGC), and memory tonsil B cells were isolated from tonsils. This study shows that the maturation state of tonsil B cells determines their capacity to undergo class switching to IgE ex vivo, with the GC-derived B cells yielding the highest percentage of IgE(+) cells. CrossRefGoogle Scholar
- 36.• Rondon C, Eguiluz-Gracia I, Plaza C, Bogas G, Galindo P, Mayorga C, et al. Local allergic rhinitis is an independent rhinitis phenotype: the results of a 10-year follow-up study. Allergy. 2018;73(2):470–8 This study is the second phase of a 10-year follow-up study of a cohort of 176 patients with LAR and 115 age- and sex-matched healthy controls. The aim of this study was to prospectively evaluate the natural history of a population with LAR, the potential conversion to AR with systemic atopy and the development of asthma. After 10-year LAR, patients experienced a significant worsening of the rhinitis, with increase in emergency assistance, development of asthma, loss of allergen tolerance, and impairment of the quality of life. A similar rate of development of AR with systemic atopy was detected in patients and controls. CrossRefGoogle Scholar
- 42.• Zicari AM, Occasi F, Di Fraia M, Mainiero F, Porzia A, Galandrini R, et al. Local allergic rhinitis in children: novel diagnostic features and potential biomarkers. Am J Rhinol Allergy. 2016;30(5):329–34 Study performed in 20 children with negative skin-prick test and serum specific immunoglobulin E. NAPT with dust mite and grass pollen was performed, and slgE, IL-5, and TSLP was measured in nasal lavage. NAPT was positive in 12 children (66.7%). Nasal slgE for allergens ( D. pteronyssinus , D. farinae, Lolium perenne ), IL-5, and TSLP levels increased significantly after NAPT. CrossRefGoogle Scholar
- 43.• Krajewska-Wojtys A, Jarzab J, Gawlik R, Bozek A. Local allergic rhinitis to pollens is underdiagnosed in young patients. Am J Rhinol Allergy. 2016;30(6):198–201 A study was performed in 121 young patients (12–18 years old) with SPT/sIgE and typical seasonal nasal symptoms were examined. NPT and nasal-specific immunoglobulin E were performed. LAR to grass pollen ( P. pratense ), Artemisia, and birch was confirmed in 17 (16.6%), 6 (5.9%), and 9 (8.9%) patients, respectively. Concentrations of nasal IgE were similar among the analyzed groups. CrossRefGoogle Scholar
- 48.•• Rondón C, Blanca-Lopez N, Campo P, Mayorga C, Jurado-Escobar R, Torres MJ, et al. Specific immunotherapy in local allergic rhinitis: a randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy. Allergy. 2018;73(4):905–15 A randomized double-blind placebo-controlled study in 56 patients with moderate-severe LAR to grass pollen, where patients received pollen immunotherapy (IT) or placebo for the first year, and pollen immunotherapy during the second one. IT had a short-term and sustained effect with significant improvements of all primary and secondary clinical outcomes, with increased serum sIgG4 levels and allergen tolerance, with no severe adverse events reported. CrossRefGoogle Scholar
- 50.Humbert M, Ying S, Kimmitt P, Barkans J, Assoufi B, et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against “intrinsic” asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med. 1996;154(5):1497–504.CrossRefGoogle Scholar
- 51.Humbert M, Taborda-Barata L, Durham SR, Pfister R, Menz G, et al. High-affinity IgE receptor (FcepsilonRI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma. 1996;153(6 Pt 1):1931–7.Google Scholar
- 53.Humbert M, Ying S, Corrigan C, Menz G, Barkans J, Pfister R, et al. Bronchial mucosal expression of the genes encoding chemokines RANTES and MCP-3 in symptomatic atopic and nonatopic asthmatics: relationship to the eosinophil-active cytokines interleukin (IL)-5, granulocyte macrophage-colony-stimulating factor, and IL-3. Am J Respir Cell Mol Biol. 1997;16(1):1–8.CrossRefGoogle Scholar
- 62.• Baba S, Toma-Hirano M, Kanaya K, Suzukawa K, Ushio M, Suzukawa M, et al. Local increase in IgE and class switch recombination to IgE in nasal polyps in chronic rhinosinusitis. Clin Exp Allergy. 2014;44(5):701–12 Local IgE production and class switch recombination to IgE were assessed in two subtypes of chronic rhinosinusitis with nasal polyps (eosinophilic and non-eosinophilic chronic rhinosinusitis). This study demonstrates local class switching to IgE, production of IgE, and IgE localization to the surface of mast cells in eosinophilic chronic rhinosinusitis in Japanese population. CrossRefGoogle Scholar
- 72.Calderon MA, Casale T, Cox L, Akdis CA, Burks AW, Nelson HS, et al. Allergen immunotherapy: a new semantic framework from the European Academy of Allergy and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL consensus report. Allergy. 2013;68(7):825–8.CrossRefGoogle Scholar
- 74.•• Shamji MH, Kappen JH, Akdis M, Jensen-Jarolim E, Knol EF, Kleine-Tebbe J, et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI position paper. Allergy. 2017;72(8):1156–73 Thorough review of candidate biomarkers used in clinical trials of AR patients. This group of experts recommends exploring the use of allergen-specific IgG4 as a biomarker for compliance, while sIgE/tIgE and IgE-FAB are considered potential surrogate candidate biomarkers. Cytokine/chemokines and cellular responses provide insight into the mechanisms of AIT. CrossRefGoogle Scholar
- 83.• Wollmann E, Kundi M, Selb R, Niederberger V, Valenta R. Reduction in allergen-specific IgE binding as measured by microarray: a possible surrogate marker for effects of specific immunotherapy. J Allergy Clin Immunol. 2015;136(3):806–9 e7. A study investigating the influence of AIT-induced allergen sIgG antibodies on IgE binding in microarray and CAP assays, and an association of IgE levels with clinical parameters. Samples were obtained in a double-blind placebo-controlled immunotherapy trial with recombinant hypoallergenic Bet v 1 derivatives before and after treatment. Results showed that allergen microarrays are useful to monitor the development of allergen-specific IgG responses during AIT, and the reduction in allergen-specific IgE binding measured by microarray analysis may be a useful surrogate marker for clinical effects of AIT. CrossRefGoogle Scholar
- 88.• Duman H, Bostanci I, Ozmen S, Dogru M. The relevance of nasal provocation testing in children with nonallergic rhinitis. Int Arch Allergy Immunol. 2016;170(2):115–21 A study performed in 28 children with symptoms suggestive of allergic rhinitis and negative SPT/sIgE and 30 healthy children. NPTs with grass mix, Dermatophagoides pteronyssinus, and D. farinae were performed, being positive in 7 (25%) patients. The study emphasizes that the diagnosis of LAR should be taken into consideration by pediatricians and pediatric allergy specialists. CrossRefGoogle Scholar
- 91.Campo P, Eguiluz-Gracia I, Bogas G, Salas M, Plaza Serón C, Pérez N, et al. Local allergic rhinitis: Implications for management. Clin Exp Allergy. 2018 Jun. https://doi.org/10.1111/cea.1319.
- 92.• Becker S, Eder K, Berghaus A, Kramer MF, Gröger M. Non-allergic rhinitis with eosinophilia syndrome is not associated with local production of specific IgE in nasal mucosa. Eur Arch Otorhinolaryngol. 2016;273(6):1469–75 Sera and nasal secretion of patients with NARES (perennial nasal symptoms, no evidence of acute or chronic rhinosinusitis with or without polyps, negative skin prick test, and eosinophilic cationic protein in nasal secretion >200 ng/ml) were tested by immunoassay-biochip technology (ImmunoCAP ® ISAC, Phadia) (112 allergen components). All results were negative demonstrating that NARES is not associated with local allergy (entopy). CrossRefGoogle Scholar